Taking a low-dose aspirin every day for nearly five years does not help healthy older adults live longer without disability, dementia, or loss of independence compared to taking a placebo.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all high-quality RCTs of low-dose aspirin in healthy elderly populations would definitively establish whether aspirin has a consistent effect on disability-free survival across diverse populations and longer durations.
A systematic review and meta-analysis of all randomized controlled trials comparing daily low-dose aspirin (75–100 mg) to placebo in adults aged 65 or older without cardiovascular disease, dementia, or disability, with disability-free survival as the primary outcome, including trials with at least 4 years of follow-up and adjudicated endpoints for death, dementia, and physical disability. Studies must be assessed for risk of bias using Cochrane tools and pooled using random-effects models.
A new RCT with longer follow-up (e.g., 7–10 years) and higher adherence could definitively confirm or refute whether aspirin affects disability-free survival in this population under optimal conditions.
A double-blind, placebo-controlled RCT of 15,000 healthy adults aged 70–80 without cardiovascular disease, randomized to 100 mg enteric-coated aspirin or placebo daily, with primary outcome of disability-free survival (composite of death, dementia, or persistent physical disability) over 7 years, using annual cognitive and functional assessments, blinded endpoint adjudication, and mandatory adherence monitoring via pill counts and biomarkers.
A prospective cohort study could determine whether long-term aspirin use in real-world elderly populations is associated with disability-free survival over 10+ years, adjusting for confounders like diet, activity, and comorbidities.
A prospective cohort study following 20,000 community-dwelling adults aged 70+ without cardiovascular disease for 10 years, collecting annual data on aspirin use (dose, duration, adherence), cognitive function (MMSE, MoCA), functional status (ADLs), and mortality via medical records and death registries, with multivariable Cox regression adjusting for socioeconomic status, BMI, smoking, and chronic conditions.
A case-control study could assess whether prior aspirin use is associated with reduced incidence of dementia or disability in elderly individuals who later developed these conditions.
A case-control study comparing 1,000 elderly individuals diagnosed with persistent physical disability or dementia after age 70 to 1,000 matched controls without these conditions, using structured interviews and pharmacy records to assess prior aspirin use (dose, duration, timing) over the preceding 5–10 years, adjusting for vascular risk factors and medication use.
A cross-sectional study could describe the prevalence of disability or cognitive impairment in elderly populations stratified by current aspirin use, but cannot determine if aspirin caused the outcome.
A cross-sectional survey of 5,000 adults aged 70+ in primary care clinics, measuring current aspirin use and assessing cognitive function (MMSE) and functional status (Katz ADL) at a single time point, with adjustment for age, sex, and comorbidities.